Viewpoint Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Viewpoint Capital Management's BMY Position: Q3 2026 in Review
Viewpoint Capital Management increased its Bristol-Myers Squibb (BMY) stake by 12% in Q3 2026, buying an estimated $177K and bringing the position to 25,733 shares worth $1.61M. The position accounts for 0.75% of the portfolio, ranked #38.
Viewpoint Capital Management first reported a position in BMY in Q4 2021 and has held it in 20 quarters since. The position peaked at $2.79M in Q2 2022. 2,568 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Viewpoint Capital Management held 25,733 shares of Bristol-Myers Squibb worth $1.61M as of Q3 2026.
- Viewpoint Capital Management bought 2,806 Bristol-Myers Squibb shares in Q3 2026, an estimated $177K.
- Bristol-Myers Squibb made up 0.75% of Viewpoint Capital Management's portfolio in Q3 2026, its #38 holding.
- Viewpoint Capital Management first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 20 quarters since.
- Viewpoint Capital Management's Bristol-Myers Squibb position peaked at $2.79M in Q2 2022.
- 2,568 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Viewpoint Capital Management's 13F filing for Q3 2026, filed 27 Oct 2026.